• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

443.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
April 07, 2026
With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex to Announce First Quarter 2026 Financial Results on May 4th
April 06, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup ↗
April 03, 2026
Via Chartmill
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
April 02, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment ↗
March 28, 2026
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup ↗
March 13, 2026
Via Chartmill
News headline image
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
April 01, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
March 31, 2026
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down
March 30, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway ↗
March 28, 2026
Some stocks can zig when the overall market zags. 
Via The Motley Fool
Topics Economy Energy Government
News headline image
2 Stocks I Plan to Hold for the Next 20 Years ↗
March 27, 2026
These companies help me sleep peacefully at night. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds
March 27, 2026
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Where Will Vertex Pharmaceuticals Be in 1 Year? ↗
March 25, 2026
The biotech's recent dip might be a buying opportunity. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
March 23, 2026
The gene-editing stock has been in a tailspin of late. 
Via The Motley Fool
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
March 21, 2026
Via ACCESS Newswire
News headline image
Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
March 20, 2026
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
Via Finterra
Topics Intellectual Property
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
March 20, 2026
We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates. 
Via The Motley Fool
News headline image
My Top 3 Drug Stocks for March 2026 ↗
March 20, 2026
These companies have impressive track records of navigating the biggest challenges in their industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗
March 19, 2026
Both have plenty to offer investors, but one has a better outlook. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks
March 17, 2026
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Momentum Stock to Research Further and 2 We Ignore
March 16, 2026
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
News headline image
Is Vertex Pharmaceuticals Heading to $600? ↗
March 15, 2026
A new product approval may be right around the corner. 
Via The Motley Fool
News headline image
This Stock Just Jumped By 8%: Is It Too Late to Buy? ↗
March 13, 2026
The drugmaker is getting its mojo back. 
Via The Motley Fool
News headline image
2 Reasons to Watch VRTX and 1 to Stay Cautious
March 13, 2026
Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This ... 
Via StockStory
Topics Stocks
News headline image
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally
March 11, 2026
In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed... 
Via MarketMinute
Topics Stocks
News headline image
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc
March 11, 2026
Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted... 
Via StockStory
Topics Artificial Intelligence
Explore the top gainers and losers within the S&P500 index in today's session. ↗
March 10, 2026
Via Chartmill
News headline image
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today
March 10, 2026
What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 8.3% in the afternoon session after the company announced positive resul... 
Via StockStory
Topics Economy
News headline image
The Great Biotech Divide: Vertex Soars on Multi-Franchise Breakthroughs as Novo Nordisk Stumbles in the Weight-Loss War
March 10, 2026
The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry... 
Via MarketMinute
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
March 10, 2026
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap